U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H6O3
Molecular Weight 138.121
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SALICYLIC ACID

SMILES

c1ccc(c(c1)C(=O)O)O

InChI

InChIKey=YGSDEFSMJLZEOE-UHFFFAOYSA-N
InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)

HIDE SMILES / InChI

Molecular Formula C7H6O3
Molecular Weight 138.121
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Palliative
SALONPAS

Approved Use

Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises

Launch Date

1203465600000
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1355011200000
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1355011200000
Primary
Salicylic Acid

Approved Use

Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles).

Launch Date

1355011200000
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
238 min
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SALICYLIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Other AEs: Redness, Scales...
Other AEs:
Redness
Scales
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Scales
30 % 1 times / 2 weeks multiple, topical
Dose: 30 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 30 %, 1 times / 2 weeks
Sources:
unhealthy, 23.05 ± 5.7 years
Health Status: unhealthy
Age Group: 23.05 ± 5.7 years
Sex: M+F
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
major
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
False-high blood salicylate levels in neonates with hyperbilirubinemia.
2000 Dec
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
Arabidopsis genome sequence as a tool for functional genomics in tomato.
2001
Unraveling regulatory networks in plant defense using microarrays.
2001
Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059.
2001 Apr
[Principal constituents from flowering aerial parts of wild pansy].
2001 Apr
Sodium salicylate increases CYP2E1 levels and enhances arachidonic acid toxicity in HepG2 cells and cultured rat hepatocytes.
2001 Apr
Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT.
2001 Apr
Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease.
2001 Apr 17
Induction of wound response gene expression in tomato leaves by ionophores.
2001 Feb
Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis.
2001 Feb
Increased leukotriene production by food additives in patients with atopic dermatitis and proven food intolerance.
2001 Feb
Ethylene-dependent salicylic acid regulates an expanded cell death response to a plant pathogen.
2001 Feb
A novel pH-sensitive membrane from chitosan--TEOS IPN; preparation and its drug permeation characteristics.
2001 Feb
Molecular responses to aphid feeding in Arabidopsis in relation to plant defense pathways.
2001 Feb
The arabidopsis ISR1 locus controlling rhizobacteria-mediated induced systemic resistance is involved in ethylene signaling.
2001 Feb
3-Hydroxybenzoic acid as an internal standard for the high-pressure liquid chromatography quantitation of salicylic acid in plants.
2001 Feb 1
Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals.
2001 Feb 1
Effect of jasmonic, salicylic, and abscisic acids on [(14)C]leucine incorporation into proteins of pea leaves.
2001 Jan
Non-uniform mapping of stress-induced, motility-related charge movement in the outer hair cell plasma membrane.
2001 Jan
Increases in the mutation frequency at which fusidic acid-resistant Staphylococcus aureus arise with salicylate.
2001 Jan
Probenazole induces systemic acquired resistance in Arabidopsis with a novel type of action.
2001 Jan
Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP.
2001 Jan
A nuclear casein kinase 2 activity is involved in early events of transcriptional activation induced by salicylic acid in tobacco.
2001 Jan
Ion channel-forming alamethicin is a potent elicitor of volatile biosynthesis and tendril coiling. Cross talk between jasmonate and salicylate signaling in lima bean.
2001 Jan
The possibility of achieving an interactive mixture with high dose homogeneity containing an extremely low proportion of a micronised drug.
2001 Jan
Cause of high variability in drug dissolution testing and its impact on setting tolerances.
2001 Jan
Induction of cell death in arabidopsis by superoxide in combination with salicylic acid or with protein synthesis inhibitors.
2001 Jan 1
Reversed-phase high-performance liquid chromatography versus spectrophotometric assay for thimerosal in Cuban recombinant hepatitis B vaccine.
2001 Jan 12
Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis.
2001 Jan 15
Salicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanism.
2001 Jan 15
Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray powder diffraction data.
2001 Jan 16
Characterization of a rice (Oryza sativa L.) Bowman-Birk proteinase inhibitor: tightly light regulated induction in response to cut, jasmonic acid, ethylene and protein phosphatase 2A inhibitors.
2001 Jan 24
Synthesis and metal binding properties of salicylate-, catecholate-, and hydroxypyridinonate-functionalized dendrimers.
2001 Jan 5
Release of salicylic acid, diclofenac acid and diclofenac acid salts from isotropic and anisotropic nonionic surfactant systems across rat skin.
2001 Jan 5
Combined cryotherapy/70% salicylic acid treatment for plantar verrucae.
2001 Jan-Feb
Quantitative analysis of hydroxyl radicals in the anterior optic nerve of the cat following transient ischemia.
2001 Jan-Feb
The Arabidopsis downy mildew resistance gene, RPP13-Nd, functions independently of NDR1 and EDS1 and does not require the accumulation of salicylic acid.
2001 Mar
Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs.
2001 Mar
Identification of free radicals produced during phacoemulsification.
2001 Mar
Quantitative analysis of analgoantipyretics in dosage form using planar chromatography.
2001 Mar
Potentiometric determination of acetylsalicylic acid by sequential injection analysis (SIA) using a tubular salicylate-selective electrode.
2001 Mar
In vivo evidence for accelerated generation of hydroxyl radicals in liver of Long-Evans Cinnamon (LEC) rats with acute hepatitis.
2001 Mar 1
Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption.
2001 Mar 14
Action of 2,3-butanedione monoxime on capacitance and electromotility of guinea-pig cochlear outer hair cells.
2001 Mar 15
Flow-through UV spectrophotometric sensor for determination of (acetyl)salicylic acid in pharmaceutical preparations.
2001 Mar 23
Microdialysis of salicylic acid from viscous emulsion samples prior to high-performance liquid chromatographic determination.
2001 Mar 30
Determination of salicylate, gentisic acid and salicyluric acid in human urine by capillary electrophoresis with laser-induced fluorescence detection.
2001 Mar 5
Acanthoamoeba attachment to contact lenses.
2001 May
Measurement of free radical production by in vivo microdialysis during ischemia/reperfusion injury to skeletal muscle.
2001 May 1
Patents

Sample Use Guides

The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.
Route of Administration: Topical
In Vitro Use Guide
Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:14:17 UTC 2021
Edited
by admin
on Fri Jun 25 21:14:17 UTC 2021
Record UNII
O414PZ4LPZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SALICYLIC ACID
EP   GREEN BOOK   HSDB   INCI   JAN   MART.   MI   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
MESALAZINE IMPURITY H [EP]
Common Name English
SALICYLIC ACID [USP-RS]
Common Name English
LAMIVUDINE RELATED COMPOUND SALICYLIC ACID [USP]
Common Name English
2-HYDROXYBENZENECARBOXYLIC ACID
Systematic Name English
COMPOUND W
Brand Name English
SALICYLIC ACID [WHO-DD]
Common Name English
SALICYLIC ACID [JAN]
Common Name English
SALICYLIC ACID [VANDF]
Common Name English
SALICYLIC ACID [INCI]
Common Name English
DR. SCHOLL'S CALLUS REMOVERS
Brand Name English
SALICYLICUM ACIDUM
HPUS  
Common Name English
FEMA NO. 3985
Code English
SALICYLIC ACID [MART.]
Common Name English
SALICYLICUM ACIDUM [HPUS]
Common Name English
SALICYLIC ACID [GREEN BOOK]
Common Name English
SALICYLIC ACID [MI]
Common Name English
SALICYLIC ACID [HSDB]
Common Name English
SALICYLATE
Systematic Name English
NSC-180
Code English
2-HYDROXYBENZOIC ACID [FHFI]
Common Name English
LAMIVUDINE IMPURITY C [EP]
Common Name English
2-HYDROXYBENZOIC ACID
FHFI  
Systematic Name English
ACIDUM SALICYLICUM [WHO-IP LATIN]
Common Name English
SALICYLIC ACID RS [USP]
Common Name English
SULFASALAZINE IMPURITY H [EP]
Common Name English
SALICYLIC ACID [EP MONOGRAPH]
Common Name English
LAMIVUDINE IMPURITY, SALICYLIC ACID- [USP]
Common Name English
SALICYLIC ACID [WHO-IP]
Common Name English
SALICYLIC ACID [USP]
Common Name English
K-557
Code English
SALICYLIC ACID [EP]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 358.710
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 333.310
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
NCI_THESAURUS C257
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
NCI_THESAURUS C52588
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 358.510
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-VATC QD01AE12
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 862.3830
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
EPA PESTICIDE CODE 76602
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 358.720
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-VATC QS01BC08
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-ATC S01BC08
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
CFR 21 CFR 358.110
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
FDA ORPHAN DRUG 359211
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-VATC QM02AC99
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
JECFA EVALUATION 2-HYDROXYBENZOIC ACID
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-ATC D01AE12
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 13.4
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
Code System Code Type Description
RXCUI
9525
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
HSDB
672
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
FDA UNII
O414PZ4LPZ
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
PUBCHEM
338
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
RXCUI
9522
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
ALTERNATIVE
LACTMED
Salicylic Acid
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
EVMPD
SUB15180MIG
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
WIKIPEDIA
SALICYLIC ACID
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
CAS
69-72-7
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
USP_CATALOG
1609002
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY USP-RS
ECHA (EC/EINECS)
200-712-3
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
MESH
D020156
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
IUPHAR
4306
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
DRUG CENTRAL
2416
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
MERCK INDEX
M9739
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C61934
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SALICYLIC ACID
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY Description: Colourless crystals, usually needle-like, or a white, crystalline powder; odourless. Solubility: Slightly soluble in water; soluble in 4 parts of ethanol (~750 g/l) TS and in 3 parts of ether R. Category: Keratolytic. Storage: Salicylic acid should be kept in a well-closed container. Definition: Salicylic acid contains not less than 99.0% and not more than 101.0% of C7H6O3, calculated with reference to the dried substance.
ChEMBL
CHEMBL424
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
DRUG BANK
DB00936
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
EPA CompTox
69-72-7
Created by admin on Fri Jun 25 21:14:18 UTC 2021 , Edited by admin on Fri Jun 25 21:14:18 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Salicylic acid content for water extract of plant callus was 3.22+/-0.06 as expressed as mg/100 g of dry base of extract. For the analysis of phenolic acids, a Nova pack C18 UG120 equipped with a Guard column, a JASCO HPLC system consisting of a column oven, a UV-Vis diode array detector set at 280 nm, a Liquid chromatography pump and a ChromNAV software program were used.
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE
MINOR
URINE
Related Record Type Details
PARENT -> IMPURITY
IDENTIFIED AS IMPURITY C Limits: impurity C: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
IMPURITY -> PARENT
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
IMPURITY -> PARENT
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
INTERNATIONAL PHARMACOPEIA
IMPURITY -> PARENT
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
PARENT -> IMPURITY
Correction factors: for the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY